Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
It is a randomized, double-blinded, single-dose, 3-arm parallel, comparative study to
evaluate the pharmacokinetics, safety and immunogenicity of BAT2306 Injection vs Cosentyx®
(EU-licensed and US-licensed) in healthy Chinese male subjects. A total of 216 healthy male
subjects are planned to be included and randomized at a ratio of 1:1:1 to receive single
150mg BAT2306 Injection or Cosentyx® (EU-licensed and US-licensed).